



WORLD HEALTH ORGANIZATION

EXECUTIVE BOARD
118th Session
Provisional agenda item 5.2

EB118/5 Add.1
27 May 2006

Report on administrative and financial implications for the Secretariat of resolutions proposed for adoption by the Executive Board or Health Assembly

1. Resolution Thalassaemia and other haemoglobinopathies	
2. Linkage to programme budget	
Area of work	Expected result
Surveillance, prevention and management of chronic, noncommunicable diseases	Support provided to countries for framing policies and strategies for prevention and management of chronic, noncommunicable diseases at national level, including integration of primary and secondary prevention into health systems
(Briefly indicate the linkage with expected results, indicators, targets, baseline)	
The resolution will provide a framework for achieving the expected result with regard to the prevention and management of thalassaemia and other haemoglobinopathies.	
3. Financial implications	
As sickle-cell anaemia is a common haemoglobinopathy kindly refer to the costing in document EB117/2006/REC/1, Annex 4	
(a) Total estimated cost for implementation over the “life-cycle” of the resolution (estimated to the nearest US\$ 10 000, including staff and activities) US\$ 2 740 000, which does not include the staff costs of US\$ 2 440 440 that are detailed in the report on administrative and financial implications of the resolution on sickle-cell anaemia.	
(b) Estimated cost for the biennium 2006-2007 (estimated to the nearest US\$ 10 000, including staff and activities) US\$ 1 390 000	
(c) Of the estimated cost noted in (b), what can be subsumed under existing programmed activities? Not applicable (no funds allocated except those under the regular budget in respect of the Programme Manager, an estimated 50% of whose work time will be needed for implementation of the resolution).	
4. Administrative implications	
(a) Implementation locales (indicate the levels of the Organization at which the work will be undertaken and identify the specific regions where relevant)	
Selected countries, five regional offices (the regional offices for the Americas, South-East Asia, Europe, the Eastern Mediterranean and the Western Pacific) and headquarters.	
(b) Additional staffing requirements (indicate additional required staff full-time equivalents, noting necessary skills profile)	
Please see the report on administration and financial implications of the resolution on sickle-cell anaemia.	
(c) Time frames (indicate broad time frames for implementation and evaluation)	
The lifespan of the global initiative is four years from 2006. The monitoring committee is to meet every two years.	